This provides clinicians with more comprehensive grounds and reasons for selecting PCSK9 inhibitors, especially for patients with a higher risk of AKI or those concurrently using nephrotoxic drugs due to hyperlipidemia. This evidence concerns the gene PCSK9 and acute kidney injury.